Alzamend posts $3M loss, flags going-concern risk
ALZN narrowed cash burn with new equity and preferred financings but still has no revenue, rising losses, a going-concern warning and ongoing internal-control weaknesses.
Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
10-Q
Rhea-AI Filing Summary
Alzamend Neuro, Inc. (ALZN) reported a net loss of $3.0 million for the three months ended July 31, 2026, slightly higher than the $2.7 million loss a year earlier, and it continues to generate no product revenue as its two drug candidates, AL001 and ALZN002, remain in clinical development.
Cash increased to $7.6 million from $0.7 million at April 30, 2026, driven by a $7.5 million first tranche of Series D Convertible Preferred Stock sold to Ault Lending and $0.7 million raised via an at-the-market common stock program, lifting stockholders’ equity to $5.8 million. Research and development expense declined 38% to $1.1 million as an earlier imaging study concluded, while general and administrative expense more than doubled to $1.9 million, largely on higher legal and professional fees. The company ended the quarter with working capital of $5.5 million but disclosed an accumulated deficit of $70.3 million, stated it expects continued losses, and concluded that these conditions raise substantial doubt about its ability to continue as a going concern, noting that additional financing will be required to sustain operations and advance its clinical programs.
Positive
- Cash position strengthened: cash rose to $7.6 million at July 31, 2026 from $0.7 million at April 30, 2026, primarily from a $7.5 million Series D preferred financing and $0.7 million raised via an at-the-market offering.
- R&D cash burn reduced: research and development expenses fell 38% year over year to $1.1 million, driven mainly by lower clinical trial costs after completion of an earlier imaging study.
- Equity base improved: stockholders’ equity increased to $5.8 million from $0.7 million at April 30, 2026, aided by new preferred and common equity issuances.
Negative
- Going-concern warning: management reported an accumulated deficit of $70.3 million, continued losses and limited cash, and stated that these factors create substantial doubt about the company’s ability to continue as a going concern without additional financing.
- Rising operating loss and no revenue: net loss increased 12% to $3.0 million for the quarter, with no product revenue and an expectation of ongoing losses for the foreseeable future.
- G&A costs more than doubled: general and administrative expenses grew 102% year over year to $1.9 million, driven by significantly higher legal and other professional fees.
- Material weakness in internal controls: the company concluded its internal control over financial reporting was not effective as of July 31, 2026 due to an unresolved material weakness, with remediation still in progress.
